About

LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, kidney failure and cancer. Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates. About LumiSTAR Biotechnology, Inc. LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, kidney failure and cancer. Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates. About LumiSTAR Biotechnology, Inc. LumiSTAR Biotechnology is a pioneering company in iPSC technology, focused on building next-generation platforms for drug discovery and regenerative medicine. By integrating advanced automation, live-cell bioimaging, and proprietary quality control systems, LumiSTAR delivers scalable production of functional human cells for both research and clinical use. Its proprietary real-time detection technology not only ensures high cell quality but also enables long-term tracking of cellular activity, supporting comprehensive efficacy and toxicity assessments in drug screening. With global collaborations and its iPSC Automation Pilot Center in Taipei, LumiSTAR is driving the transition toward human-relevant, animal-free preclinical testing and advancing precision cell therapies.